Novo Seeds, Lundbeck, Merck and Astellas all exited EpiTherapeutics after it was acquired by biopharmaceutical firm Gilead.
Month: May 2015
Lockheed Martin finds Cybereason to invest
The aerospace company was among the investors in a $25m series B round for Cybereason, which plans to use the cash to double its workforce.
Dida Pinche picks up $100m
Dida Pinche, which operates in China’s increasingly crowded ride sharing sector, secured the money in a round featuring Bitauto and IDG Capital.
Layer launches startup fund
The Bloomberg-backed communication platform has set up a fund to support startups developing apps on its platform.
Fitbit warms up for $100m IPO
The wearable fitness device maker has raised $83m in funding from investors including SoftBank and Qualcomm.
Robinhood stays merry with $50m
Google-backed share trading service Robinhood has raised series B funding to support an international expansion that will begin in Australia.
E.ON sells 49% stake in waste-to-energy company
The energy utility divested its stake in EEW Energy from Waste to private equity firm EQT, which now wholly owns the waste-to-energy company.
JNC expands R&D to Silicon Valley
The chemicals and materials company, which already operates four research and development centres in Japan, will look to fund startup innovation through the new office.
NTT Docomo backs adtech company SessionM’s series C
The mobile advertising technology company has now raised more than $38m across three rounds, after closing a $12m round backed by NTT Docomo.
Digit saves up $11.3m for series A
Google, which had backed the automated savings service’s $2.5m seed round in December, returned for its latest round.
HT Media helps Tandem cycle to $100m fund
HT Media is among the investors in the third fund raised by US-based accelerator Tandem Capital, which is now looking to invest more heavily in India.
Banjo tunes up for $100m series C
SoftBank led the location-based data platform’s latest round, which will be used to beef up its engineering and data science teams.
CoLucid dream of IPO comes true
Novo-backed CoLucid Pharmaceuticals secured $55m in the offering, and will use the proceeds to advance its migraine treatment through clinical trials.
Evolent to evolve with $100m IPO
The health services management company, founded by UPMC Health Plan and The Advisory Board Company, has targeted $100m for its initial public offering.